Pan‐cancer analysis identifies the IRF family as a biomarker for survival prognosis and immunotherapy
Journal of Cellular and Molecular Medicine · 2024
DOI: 10.1111/jcmm.18084 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2024. Verfasst von Hua-Guo Xu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Jiangsu Province of China, the National Key Clinical Department of Laboratory Medicine of China in Nanjing, Key laboratory for Laboratory Medicine of Jiangsu Province and by the Priority…, National Nature Science Foundation of China.
Abstract (Originalsprache)
IRF family genes have been shown to be crucial in tumorigenesis and tumour immunity. However, information about the role of IRF in the systematic assessment of pan‐cancer and in predicting the efficacy of tumour therapy is still unknown. In this work, we performed a systematic analysis of IRF family genes in 33 tumour samples, including expression profiles, genomics and clinical characteristics. We then applied Single‐Sample Gene‐Set Enrichment Analysis (ssGSEA) to calculate IRF‐scores and analysed the impact of IRF‐scores on tumour progression, immune infiltration and treatment efficacy. Our results showed that genomic alterations, including SNPs, CNVs and DNA methylation, can lead to dysregulation of IRFs expression in tumours and participate in regulating multiple tumorigenesis. IRF‐score expression differed significantly between 12 normal and tumour samples and the impact on tumour prognosis and immune infiltration depended on tumour type. IRF expression was correlated to drug sensitivity and to the expression of immune checkpoints and immune cell infiltration, suggesting that dysregulation of IRF family expression may be a critical factor affecting tumour drug response. Our study comprehensively characterizes the genomic and clinical profile of IRFs in pan‐cancer and highlights their reliability and potential value as predictive markers of oncology drug efficacy. This may provide new ideas for future personalized oncology treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
- Branch of National Clinical Research Center for Laboratory Medicine, Nanjing, China.
ORCID-Profile: Can Chen
Förderung
- Natural Science Foundation of Jiangsu Province of China
- the National Key Clinical Department of Laboratory Medicine of China in Nanjing, Key laboratory for Laboratory Medicine of Jiangsu Province and by the Priority…
- National Nature Science Foundation of China
- Jiangsu Provincial Research Hospital
- National Science Foundation
- National Natural Science Foundation of China
Zitieren
APA
Xu, H. G., Chen, C., Chen, L. Y., & Pan, S. (2024). Pan‐cancer analysis identifies the IRF family as a biomarker for survival prognosis and immunotherapy. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.18084
Vancouver
Xu HG, Chen C, Chen LY, Pan S. Pan‐cancer analysis identifies the IRF family as a biomarker for survival prognosis and immunotherapy. Journal of Cellular and Molecular Medicine. 2024. doi:10.1111/jcmm.18084
BibTeX
@article{Xu2024,
author = {Xu, Hua-Guo and Chen, Can and Chen, Lin-Yuan and Pan, Shiyang},
title = {Pan‐cancer analysis identifies the IRF family as a biomarker for survival prognosis and immunotherapy},
journal = {Journal of Cellular and Molecular Medicine},
year = {2024},
doi = {10.1111/jcmm.18084}
}
EUVIMED